Allarity Therapeutics Inc
NASDAQ:ALLR
Allarity Therapeutics Inc
EPS (Diluted)
Allarity Therapeutics Inc
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Allarity Therapeutics Inc
NASDAQ:ALLR
|
EPS (Diluted)
-$205
|
CAGR 3-Years
79%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$4
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$10
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
-$3
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$40
|
CAGR 3-Years
-17%
|
CAGR 5-Years
15%
|
CAGR 10-Years
30%
|
|
Allarity Therapeutics Inc
Glance View
Allarity Therapeutics, Inc. engages in the development of drugs for personalized treatment of cancer guided by its proprietary Drug Response Predictor (DRP) technology. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2021-12-21. The firm is engaged in targeting some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates together with its Drug Response Predictor (DRP) companion diagnostics in a precision medicine approach. The company uses its DRP companion diagnostics platform to advance therapeutic candidates by targeting and evaluating patient sub-populations having gene signatures, determined by its DRP companion diagnostics platform. Its lead therapeutic candidate, dovitinib, is a selective inhibitor of several classes of tyrosine kinases, including fibroblast growth factor receptors (FGFR) and vascular endothelial growth factor receptor (VEGFR). Its second priority therapeutic candidate, stenoparib, is a selective inhibitor of the key deoxyribonucleic acid (DNA) damage repair enzyme poly-ADP-ribose polymerase (PARP). Its third priority therapeutic candidate is IXEMPRA (ixabepilone).
See Also
What is Allarity Therapeutics Inc's EPS (Diluted)?
EPS (Diluted)
-205.2
USD
Based on the financial report for Dec 31, 2023, Allarity Therapeutics Inc's EPS (Diluted) amounts to -205.2 USD.
What is Allarity Therapeutics Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
79%
Over the last year, the EPS (Diluted) growth was 100%. The average annual EPS (Diluted) growth rates for Allarity Therapeutics Inc have been 79% over the past three years .
You don't have any saved screeners yet